Importantly, these differences in metabolic rewiring have led to the development of several candidate therapeutics, some of which are currently being tested clinical trials, that target biochemical mechanisms that are orthogonal to the standard of care for SLE based on immunosuppressants. Therefore, it is crucial that we gain a comprehensive understanding of impaired metabolic rewiring in SLE.